PURLs

This asthma treatment has a lasting side effect in children

Author and Disclosure Information

 

References

What’s new: Now we know: Children don’t “catch up"

Retrospective studies have reported that children on ICS for mild persistent to moderate asthma would have an initial slowing in growth velocity but then “catch up” by growing for a longer period of time.3-5 This is the first prospective study with good follow-up to show that ICS use affects long-term growth and adult height. While the effect is not large, some children and their families might be concerned about it.

Caveats: ICS use was atypical

The randomized controlled portion of the study used a prescribed dose of budesonide without regard to symptoms. This is not the typical pattern of ICS use. In addition, compliance with ICS varies significantly.12 Because the effect on adult height appears to be dose dependent, however, we think the results of this study are valid.

In addition, there was a placebo control group (and big differences in exposure to ICS) only for the duration of the RCT. During the subsequent study, all patients received equivalent doses of ICS. This means that the variation in mean adult height achieved can be primarily ascribed to participants’ use of ICS during the 4- to 6-year CAMP trial. Of note, the effect of ICS was greatest in prepubertal participants, so there may be a diminished effect as teens approach their final height.

The study did not look at the effect of ICS use in patients with severe asthma—the group most likely to use ICS. However, the benefits of ICS for those with severe asthma likely outweigh any negative effects on adult height.

Challenges to implementation: What to tell patients

The message we convey to patients (and parents) about ICS use is a nuanced one. We can stress that ICS remain very important in the treatment of asthma and, while it appears that their use causes a slight decrease in adult height, most children with persistent asthma benefit from ICS.

Acknowledgement

The PURLs Surveillance System is supported in part by Grant Number UL1RR024999 from the National Center for Research Resources, a Clinical Translational Science Award to the University of Chicago. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health.

Pages

Copyright © 2013 Family Physicians Inquiries Network. All rights reserved.

Online-Only Materials

AttachmentSize
Microsoft Office document icon JFP06209500_methodology98.5 KB

Recommended Reading

Data underscore environment's role in allergic disease
MDedge Family Medicine
Immunotherapy for kids' food allergies is taking baby steps
MDedge Family Medicine
Guidelines: SABAs, not LABAs, for exercise-induced bronchoconstriction
MDedge Family Medicine
Dupilumab cuts moderate, severe asthma exacerbations
MDedge Family Medicine
Early adenotonsillectomy beneficial for obstructive sleep apnea syndrome
MDedge Family Medicine
CDC urges doctors to help patients quit smoking
MDedge Family Medicine
Allergy risk in obese children may be related to vitamin D deficiency
MDedge Family Medicine
Chest x-rays for asthma doubled in 15 years
MDedge Family Medicine
Spot checks suffice for monitoring pediatric bronchiolitis
MDedge Family Medicine
Intermittent positive-pressure ventilation similar to continuous positive airway pressure in preventing lung injury in preemies
MDedge Family Medicine